Crohn’s disease is a long‑lasting condition that causes inflammation of the digestive tract, leading to stomach pain, diarrhea, weight loss, and fatigue. The study uses the medicine guselkumab, which is given as a small injection under the skin with a pre‑filled syringe. This drug works by targeting parts of the immune system that cause the gut inflammation, with the aim of keeping the disease quiet and improving daily life.
The purpose of the study is to evaluate the one‑year effectiveness of guselkumab in real‑world patients with Crohn’s disease. Participants receive regular injections of the medication for up to twelve months and attend clinic visits at about 12, 24 and 48 weeks. During these visits doctors check how the patient feels, review stool tests that measure a protein called fecal calprotectin (a sign of gut inflammation), and look at the intestines using one of three imaging methods: an endoscopy (a thin camera inserted to see inside the gut), an MRI (a scan that uses magnets to create pictures of the body), or IUS (an ultrasound performed on the skin). Questions about quality of life are also completed to see if the treatment helps patients feel better overall.
France 
